Crossmark

Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAFV600E mutation status

Crossref DOI link: https://doi.org/10.1007/s00432-023-04720-3

Published Online: 2023-04-09

Published Print: 2023-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kang, Sora

Lee, Myung-Won

Song, Ik-Chan

Lee, Hyo-Jin

Yun, Hwan-Jung

Jo, Deog-Yeon

Kim, Jung Sun

Kwon, Jung Hye

Kim, Ji-Yeon

Lee, Kyung-Ha

Ryu, Hyewon
Funding

Funding for this research was provided by:

Ministry of Health & Welfare, Republic of Korea (HR20C0025)
License Information

Text and Data Mining valid from 2023-04-09

Version of Record valid from 2023-04-09
More Information

Article History

Received: 23 November 2022

Accepted: 21 March 2023

First Online: 9 April 2023

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.

Document is current

Any future updates will be listed below